A month has gone by since the last earnings report for Myriad Genetics (MYGN). Shares have added about 23.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for ...

Shares of Myriad Genetics were higher after it announced early access to the FirstGene Multiple Prenatal Screen. The stock was up 9.2% to $4.87 Tuesday and is down about 64% this year.

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable ...

Myriad Oncology provides a portfolio of advanced genetic and tumor genomic testing solutions, including risk assessment, ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the ...

Myriad Genetics is down 22.9% since the beginning of the year, and at $10.41 per share, it is trading 63.6% below its 52-week high of $28.60 from September 2024.

For more information about the importance of prenatal screening, Myriad offers the “Know More Sooner” website, which provides the benefits and dispels the common myths of prenatal genetic ...

SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual ...